Noemi Reguart: Presidential Phase 3, Ivonescimab vs Pembrolizumab for PD-L1+ advanced NSCLC

Noemi Reguart shared a post on X:

”WCLC24 Presidential. Phase 3 Ivonescimab (AK112) versus Pembrolizumab as first-line treatment for PD-L1 positive advanced non-small cell lung cancer (aNSCLC): Primary Analysis of HARMONi-2. Median progression-free survival (mPFS) 11.14 vs 5.82 months, hazard ratio (HR) 0.51, p < 0.0001. First trial demonstrating a significant improvement with a novel drug compound versus Pembrolizumab. Awaiting overall survival (OS) and confirmatory data outside China.”

Source: Noemi Reguart/X

Noemi Reguart is a Medical Oncologist at Hospital Clinic Barcelona. Prof. Reguart’s work focuses on translational genomics and targeted therapies in lung cancer. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. She is an active member of several international organizations including the Lung Cancer Group of the European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC).